SAN FRANCISCO — Shares of Braveheart Bio Inc. rose 5.50% to $29.24 in Thursday trading, adding $1.53, as the clinical-stage cardiovascular biotechnology company continued to draw investor interest following the initiation of a pivotal late-stage trial for its lead heart disease drug candidate roughly six weeks after going public.

Braveheart Bio is developing therapies for hypertrophic cardiomyopathy, a serious cardiovascular condition in which the heart muscle grows abnormally thick, making it harder for the heart to pump blood efficiently. The company's lead candidate, BHB-1893, is an oral, next-generation small-molecule cardiac myosin inhibitor being developed to treat both the obstructive and non-obstructive forms of the disease. Braveheart has said it designed the drug to address limitations in currently available treatments in its class, aiming for rapid onset of effect, consistent depth of response, preservation of the heart's pumping function, prompt reversibility if treatment needs to be stopped, and a more straightforward approach to dosing and patient monitoring than existing options.

The company reported second-quarter 2026 financial results and a business update on September 8, disclosing that it had formally initiated LIONHEART-HCM, a global Phase 3 trial evaluating BHB-1893 against the beta-blocker metoprolol in adults with symptomatic obstructive hypertrophic cardiomyopathy. That trial follows positive Phase 2 results in the obstructive form of the disease announced in March. Braveheart Chief Executive........

© International Business Times